Affimed N.V. (AFMD)

NASDAQ: AFMD · IEX Real-Time Price · USD
2.16
+0.02 (0.93%)
Oct 4, 2022 4:00 PM EDT - Market closed
0.93%
Market Cap 322.57M
Revenue (ttm) 36.11M
Net Income (ttm) -80.27M
Shares Out 149.34M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,044,668
Open 2.17
Previous Close 2.14
Day's Range 2.11 - 2.24
52-Week Range 1.93 - 7.35
Beta 2.30
Analysts Buy
Price Target 10.69 (+394.9%)
Earnings Date Oct 27, 2022

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa ... [Read more...]

Industry Biotechnology
IPO Date Sep 12, 2014
Employees 197
Stock Exchange NASDAQ
Ticker Symbol AFMD
Full Company Profile

Financial Performance

In 2021, Affimed's revenue was 40.37 million, an increase of 42.33% compared to the previous year's 28.36 million. Losses were -57.52 million, 39.1% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for AFMD stock is "Buy." The 12-month stock price forecast is 10.69, which is an increase of 394.91% from the latest price.

Price Target
$10.69
(394.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (E...

HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...

1 month ago - GlobeNewsWire

Affimed to Present at Upcoming Investor Conferences

HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...

1 month ago - GlobeNewsWire

Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

This billionaire-guided hedge fund went bargain-shopping in the second quarter.

Other symbols: CERSREPL
1 month ago - The Motley Fool

Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022.

1 month ago - Zacks Investment Research

Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

HEIDELBERG, Germany, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

1 month ago - GlobeNewsWire

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...

2 months ago - GlobeNewsWire

7 Undervalued Biotech Stocks to Buy Before They Boom

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. The post 7 Undervalued Biotech Stocks to Buy Before They Boom appeared ...

2 months ago - InvestorPlace

6 Blue-Chip Stocks to Sell Now

This article is about 6 blue-chip stocks to sell now. The stocks are overvalued or could fall due to the recession or from a downgrade in analysts' forecasts of their earnings.

Other symbols: ACBAGSCURIEWTXGEVO
2 months ago - InvestorPlace

Affimed Establishes Scientific Advisory Board

HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...

3 months ago - GlobeNewsWire

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology...

HEIDELBERG, Germany, June 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

3 months ago - GlobeNewsWire

Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022.

4 months ago - Zacks Investment Research

Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

HEIDELBERG, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Societ...

HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...

4 months ago - GlobeNewsWire

Affimed to Present at the 2022 Jefferies Healthcare Conference

HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

4 months ago - Zacks Investment Research

Affimed Announces Annual General Meeting of Shareholders

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

HEIDELBERG, Germany, May 16, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the An...

HEIDELBERG, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

3 Small-Caps That Might Be Acquisition Candidates

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

Other symbols: BPMCOPRX
4 months ago - The Motley Fool

Affimed Provides Update on ASCO AFM13-104 Oral Presentation

HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...

4 months ago - GlobeNewsWire

CORRECTING and REPLACING -- Affimed N.V.

In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American Society...

5 months ago - GlobeNewsWire

Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for...

HEIDELBERG, Germany, April 27, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...

5 months ago - GlobeNewsWire

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase A...

HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their innate ...

5 months ago - GlobeNewsWire

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...

5 months ago - GlobeNewsWire